NEW YORK (GenomeWeb News) – BioFocus will offer its customers Activiomics' proteomics services for identifying novel biomarkers for diagnostics and targets for new drugs, the companies said today.

Under a strategic agreement, BioFocus will offer its customers Activiomics' Targeted In-depth QUAntification of cell Signaling, or TIQUAS, technology for proteomics studies in oncology, inflammation, and metabolic disease.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.